Thus, immunotherapy produces better outcomes in PD-L1-positive PSC patients than in PD-L1-negative ones, whereas immunotherapy may still be efficacious in PD-L1-negative patients, which might be due to the interaction between the immune system and tumor cells [78]. Here, CD274 is linked to neoplasm.